zilucoplan (RA101495)

Phase 3Active

0 views this week 0 watching⚡ Active

Interest: 44/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Generalized Myasthenia Gravis

Conditions

Generalized Myasthenia Gravis

Trial Timeline

Dec 23, 2019 → Jun 2, 2026

NCT ID

NCT04225871

About zilucoplan (RA101495)

zilucoplan (RA101495) is a phase 3 stage product being developed by UCB for Generalized Myasthenia Gravis. The current trial status is active. This product is registered under clinical trial identifier NCT04225871. Target conditions include Generalized Myasthenia Gravis.

What happened to similar drugs?

12 of 20 similar drugs in Generalized Myasthenia Gravis were approved

Approved (12) Terminated (3) Active (7)

✅Duloxetine + PlaceboEli LillyApproved

✅IxekizumabEli LillyApproved

✅Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatmentSumitomo PharmaApproved

✅EscitalopramAbbVieApproved

✅QuetiapineAstraZenecaApproved

✅Alprazolam (Xanax) + PlaceboRocheApproved

✅Ziprasidone + PlaceboPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05514873	Phase 3	Completed	Oct 31, 2022	Oct 23, 2024	Generalized Myasthenia Gravis
NCT04225871	Phase 3	Active	Dec 23, 2019	Jun 2, 2026	Generalized Myasthenia Gravis
NCT03225287	Phase 2	Terminated	Jul 17, 2017	Oct 26, 2021	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03030183	Phase 2	Completed	Apr 17, 2017	Mar 28, 2018	Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT03078582	Phase 2	Completed	Mar 8, 2017	Mar 28, 2018	Paroxysmal Nocturnal Hemoglobinuria (PNH)

Competing Products

20 competing products in Generalized Myasthenia Gravis

See all competitors

Product	Company	Stage	Hype Score
atomoxetine + placebo	Eli Lilly	Phase 2/3	38
Satralizumab	Chugai Pharmaceutical	Phase 3	32
Perampanel	Eisai	Pre-clinical	26
Perampanel + Placebo comparator	Eisai	Phase 3	40
zonisamide	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Fycompa	Eisai	Pre-clinical	26
Perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Cenobamate	Ono Pharmaceutical	Phase 3	47
Duloxetine + Placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Approved	43
Ixekizumab	Eli Lilly	Approved	43
eszopiclone + eszopiclone + Placebo	Sumitomo Pharma	Phase 2	35
Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment	Sumitomo Pharma	Approved	43
ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT)	AbbVie	Phase 2	42
Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day	AbbVie	Phase 2	27
ABBV-932 + Placebo	AbbVie	Phase 1	29
Escitalopram	AbbVie	Approved	43
Adalimumab	AbbVie	Phase 3	40